Repligen Corporation (NASDAQ:RGEN) – Analysts at William Blair dropped their Q3 2017 earnings per share (EPS) estimates for shares of Repligen Corporation in a research note issued to investors on Monday. William Blair analyst A. Murphy now forecasts that the biotechnology company will post earnings per share of $0.12 for the quarter, down from their previous forecast of $0.15. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Repligen Corporation’s FY2017 earnings at $0.60 EPS and FY2019 earnings at $0.92 EPS.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.16 earnings per share.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/10/q3-2017-earnings-estimate-for-repligen-corporation-nasdaqrgen-issued-by-william-blair.html.

Other equities analysts have also recently issued research reports about the stock. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research cut shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC reissued a “hold” rating and set a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. First Analysis reissued an “equal weight” rating and set a $40.00 target price on shares of Repligen Corporation in a research report on Friday, April 21st. Finally, Janney Montgomery Scott lifted their target price on shares of Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $41.20.

Repligen Corporation (RGEN) opened at 42.71 on Wednesday. The firm’s 50-day moving average price is $41.52 and its 200-day moving average price is $36.21. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The firm has a market cap of $1.46 billion, a P/E ratio of 112.69 and a beta of 1.30.

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Repligen Corporation during the first quarter valued at approximately $103,000. Victory Capital Management Inc. boosted its position in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Repligen Corporation during the second quarter valued at approximately $123,000. State of Alaska Department of Revenue boosted its position in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares in the last quarter. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History and Estimates for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.